Mechanisms of action of thiazolidinediones;Mécanisme d'action des thiazolidinediones

Diabetes and Metabolism

Volumn 27, Issue 2 II, 2001, Pages 271-278

  Girard, J ^a  

^a CNRS   (France)

Author keywords

Adipocyte; Glucose utilization; Glucose fatty acid cycle; Insulin resistance; PPAR; Skeletal muscle; Thiazolidinediones; TNF

Indexed keywords

ANTIDIABETIC AGENT; PIOGLITAZONE; ROSIGLITAZONE; THIAZOLIDINE DERIVATIVE; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; DRUG EFFECT; DRUG MECHANISM; FATTY ACID METABOLISM; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY;

ADIPOSE TISSUE; ANIMALS; DIABETES MELLITUS, TYPE 2; GENE EXPRESSION; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MUSCLE, SKELETAL; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLES; TRANSCRIPTION FACTORS;

EID: 0035040960     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Thiazolidinediones in the treatment of insulin resistance and type II diabetes
2. Troglitazone: Antihyperglycemic activity and potential role in the treatment of type 2 diabetes
3. Thiazolidinediones: A new class of antidiabetic drugs
4. Troglitazone. A novel antidiabetic drug for treating insulin resistance
5. Treatment of insulin resistance with PPARγ agonists
6. Troglitazone inhibits fatty acid oxidation and esterification, and gluconeogenesis in isolated hepatocytes from starved rats
7. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus
8. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes
9. Mechanism of troglitazone action in type 2 diabetes
10. Antidiabetic thiazolidinediones block the inhibitory effect of TNF-a on differentiation, insulin-stimulated glucose uptake, and gene expression in 3T3-L1 cells
11. Troglitazone enhances differentiation, basal glucose uptake, and Glut1 protein levels in 3T3-L1 adipocytes
12. Effects of thiazolidinediones on glucocorticoid-induced insulin resistance and glut4 glucose transporter expression in rat skeletal muscle
13. Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and GLUT 4 translocation
14. Potential role of protein kinase B in GLUT4 translocation in adipocytes
15. Protein Kinase B/Akt Participates in GLUT4 Translocation by Insulin in L6 Myoblasts
16. A role for protein kinase Bβ/Akt2 in insulin-stimulated GLUT4 translocation in adipocytes
17. Activation of protein kinase C (a, b, and z) by insulin in 3T3/L1 cells. Transfection studies suggest a role for PKC-z in glucose transport
18. Evidence for involvement of protein kinase C (PKC)-z and noninvolvement of diacylglycerol-sensitive PKCs in insulin-stimulated glucose transport in L6 myotubes
19. Effects of transiently expressed atypical (x. 1), conventional (a, b) and novel (d) protein kinase C isoforms on insulin-stimulated translocation of epitopetagged GLUT4 glucose transporters in rat adipocytes: Specific interchangeable effects of protein kinases C-x and C-l
20. Protein kinase C z as a downstream effector of phosphatidylinositol 3-kinase during insulin stimulation in rat adipocytes. Potential role in glucose transport
21. Thiazolidinedione treatment enhances insulin effects on protein kinase C-z/l activation and glucose transport in adipocytes of nondiabetic and Goto-Kakizaki (GK) type II diabetic rats
22. Thiazolidinediones and insulin resistance: PPARγ activation stimulates expression of the CAP gene
23. A novel, multifunctional c-Cbl binding protein in insulin receptor signaling in 3T3-L1 adipocytes
24. CAP defines a second signalling pathway required for insulin-stimulated glucose transport
25. Enhancement of adipocyte differentiation by an insulin-sensitizing agent
26. Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells
27. PPARγ: Adipogenic regulator and thiazolidinedione receptor
28. The PPARs: From orphan receptors to drug discovery
29. Sensitization of diabetic and obese mice to insulin by RXR agonists
30. Fondements physiopathologiques du diabete de type 2
31. Cellular mechanisms of insulin resistance
32. Pioglitazone induces in viva adipocyte differentiation in the obese Zucker fa/fa rat
33. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats
34. Pioglitazone-induced increase of insulin sensitivity in the muscles of the obese Zucker fa/fa rat cannot be explained by local adipocyte differentiation
35. Differential expression of PPARs: Tissue distribution of PPARα, β, and γ in the adult rat
36. Identification, characterization, and tissue distribution of human PPAR isoforms PPARγ2 versus PPARγl and activation with RXR agonists and antagonists
37. PPAR gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids
38. The PPARs and their effects on lipid metabolism and adipocyte differentiation
39. PPARγ activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes
40. A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat
41. The insulin sensitizer, BRL 49653, reduces systemic fatty acid supply and utilization and tissue lipid availability in the rat
42. Mechanisms by which thiazolidinediones enhance insulin action
43. Potential role of TNF-a in the pathogenesis of insulin resistance and type 2 diabetes
44. Molecular mechanisms of insulin resistance and the role of the adipocyte
45. Troglitazone action is independent of adipose tissue
46. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones
47. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice
48. PPARγ is required for placental, cardiac, and adipose tissue development
49. Improved insulin-sensitivity in mice heterozygous for PPARγ deficiency
50. PPARγ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance
51. A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity
52. Expression of genes involved in lipid metabolism correlate with PPARγ expression in human skeletal muscle
53. Acute effect of troglitazone on glucose metabolism in the absence or presence of insulin in perfused rat hindlimb
54. Acute non-insulin-like stimulation of rat muscle glucose metabolism by troglitazone in vitro
55. Troglitazone directly inhibits CO2 production from glucose and palmitate in isolated rat skeletal muscle
56. Troglitazone regulation of glucose metabolism in human skeletal muscle cultures from obese type II diabetic subjects
57. Chronic and acute effects of thiazolidinediones BM 13.1258 and BM 15.2054 on rat skeletal muscle glucose metabolism
58. Troglitazone effects on gene expression in human skeletal muscle of type II diabetes involve up-regulation of PPARγ
59. Acides gras, insulinosécrétion et lipotoxicité
60. Evolution of β-cell dysfunction in the male Zucker diabetic fatty rat
61. Role of apoptosis in failure of β-cell mass compensation for insulin resistance and β-cell defects in the male Zucker diabetic fatty rat
62. Impaired β-cell function and deposition of fat droplets in the pancreas as a consequence of hypertriglyceridemia in OLETF rat, a model of spontaneous NIDDM
63. β-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rots: Impairment in adipocyte-β-cell relationships
64. Caloric restriction in obese pre-diabetic rats prevents β-cell depletion, loss of βcell GLUT2 and glucose incompetence
65. Increased lipogenic capacity of the islets of obese rats: A role in the pathogenesis of NIDDM
66. Fatty acid-induced cell apoptosis: A link between obesity and diabetes
67. How obesity causes diabetes in Zucker diabetic fatty rats
68. Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats
69. Troglitazone prevents mitochondrial alterations, β-cell destruction, and diabetes in obese prediabetic rats